GlobeNewswire: Innocoll Holdings plc Contains the last 10 of 60 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:07:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/07/24/1056162/0/en/Innocoll-and-Gurnet-Point-Announcement-relating-to-the-Scheme-becoming-Effective.html?f=22&fvtc=4&fvtv=22780Innocoll and Gurnet Point Announcement relating to the Scheme becoming Effective2017-07-24T13:17:09Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2017/07/21/1055672/0/en/Innocoll-Announcement-Relating-to-the-Outcome-of-the-Court-Sanction-Hearing.html?f=22&fvtc=4&fvtv=22780Innocoll Announcement Relating to the Outcome of the Court Sanction Hearing2017-07-21T12:46:44Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2017/06/28/1030068/0/en/Innocoll-Announces-Scheme-Meeting-and-Extraordinary-General-Meeting-Voting-Results.html?f=22&fvtc=4&fvtv=22780Innocoll Announces Scheme Meeting and Extraordinary General Meeting Voting Results2017-06-28T14:04:16Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2017/05/30/1000154/0/en/Innocoll-and-Gurnet-Point-Announce-Dispatch-of-Rule-15-Proposals.html?f=22&fvtc=4&fvtv=22780Innocoll and Gurnet Point Announce Dispatch of Rule 15 Proposals2017-05-30T19:55:37Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION]]>https://www.globenewswire.com/news-release/2017/05/12/984559/0/en/Innocoll-Announces-Proxy-Statement-Mail-Out-to-Shareholders.html?f=22&fvtc=4&fvtv=22780Innocoll Announces Proxy Statement Mail-Out to Shareholders2017-05-12T21:35:15Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2017/05/10/982115/0/en/Innocoll-Announces-Scheme-Meeting-Details.html?f=22&fvtc=4&fvtv=22780Innocoll Announces Scheme Meeting Details2017-05-10T20:30:00Z<![CDATA[NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.]]>https://www.globenewswire.com/news-release/2017/03/29/946387/0/en/Innocoll-announces-regulatory-path-forward-after-receiving-formal-FDA-Type-A-meeting-minutes-regarding-its-XARACOLL-bupivacaine-HCl-collagen-matrix-implant-New-Drug-Application.html?f=22&fvtc=4&fvtv=22780Innocoll announces regulatory path forward after receiving formal FDA Type A meeting minutes regarding its XARACOLL® (bupivacaine HCl collagen-matrix implant) New Drug Application2017-03-29T13:15:00Z<![CDATA[ATHLONE, Ireland, March 29, 2017 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (NASDAQ:INNL) ("Innocoll" or the "Company"), a global, commercial-stage, specialty pharmaceutical and medical device company, today announced receipt of formal Type A Meeting minutes from the United States Food and Drug Administration (FDA) relating to its New Drug Application (NDA) for XARACOLL (bupivacaine HCl collagen-matrix implant).  XARACOLL is the company’s product in development for the treatment of postsurgical pain.]]>https://www.globenewswire.com/news-release/2017/03/16/940411/0/en/Innocoll-Holdings-plc-Announces-Fourth-Quarter-and-Full-Year-2016-Financial-and-Operating-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=22780Innocoll Holdings plc Announces Fourth Quarter and Full-Year 2016 Financial and Operating Results and Provides Corporate Update2017-03-16T20:17:58Z<![CDATA[ATHLONE, Ireland, March 16, 2017 (GLOBE NEWSWIRE) -- Innocoll Holdings plc (Nasdaq:INNL), a global, commercial stage, specialty pharmaceutical company with late stage development programs targeting areas of significant unmet medical need announced financial and operating results for the three months and full year ended December 31, 2016. Innocoll manufactures and supplies a range of pharmaceutical products and medical devices using its proprietary collagen-based biodegradable and fully bioresorbable technology platform.]]>https://www.globenewswire.com/news-release/2017/03/16/940319/0/en/Innocoll-Holdings-Announces-Statement-re-Possible-Offer.html?f=22&fvtc=4&fvtv=22780Innocoll Holdings Announces Statement re: Possible Offer2017-03-16T16:52:31Z<![CDATA[ATHLONE, Ireland, March 16, 2017 (GLOBE NEWSWIRE) -- The Board of Innocoll Holdings plc (“Innocoll” or the “Company”) (NASDAQ:INNL) notes anomalous movements in Innocoll’s share price this week and confirms that it is in discussions which may or may not lead to an offer for the entire issued share capital of the Company.]]>https://www.globenewswire.com/news-release/2016/12/29/902225/0/en/Innocoll-Receives-Refusal-to-File-Letter-from-U-S-FDA-for-XARACOLL-bupivacaine-HCl-collagen-matrix-implants-New-Drug-Application.html?f=22&fvtc=4&fvtv=22780Innocoll Receives Refusal to File Letter from U.S. FDA for XARACOLL® (bupivacaine HCl collagen-matrix implants) New Drug Application2016-12-29T22:00:00Z<![CDATA[ATHLONE, Ireland, Dec. 29, 2016 (GLOBE NEWSWIRE) -- Innocoll (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company, today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.]]>